Loading clinical trials...
Loading clinical trials...
Dalfampridine is a new medication that was FDA approved in 2010 to improve walking speed in people with Multiple Sclerosis (MS). People with MS walk slowly in part because MS damages the myelin insula...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Oregon Health and Science University
Collaborators
NCT07669519 · Fatigue, Colon Cancer
NCT07663266 · Multiple Sclerosis, Spinal Cord Injury
NCT07189325 · Relapsing-Remitting Multiple Sclerosis (RRMS), Anti-CD20 Therapy
NCT07659301 · Athletic Performance, Hyperbaric Oxygenation, and more
NCT06170970 · Multiple Sclerosis, Multiple Sclerosis Fatigue
Oregon Health and Science University
Portland, Oregon
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions